systemic

(redirected from Systemic therapy)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
See: physical
References in periodicals archive ?
Given that at least seven biologic and small molecular therapies of varying mechanisms are in phase 2 or 3 development, the options for treatment of patients who need systemic therapy are likely to expand in the coming years.
A separate analysis of the same database showed that, among patients who received CN after systemic therapy, OS was significantly longer than among those who only received systemic therapy (median OS 19.
Thus, the group that benefited from both standard and systemic therapy had an abstinence average of almost seven months (M = 6.
Looking at therapy sequence in those who had the same type of systemic therapy, but with chemotherapy before or after surgery, you see a suggestion that giving systemic therapy first with a clinical response, which is a favorable prognostic indication, leads to a selection bias in choosing patients for surgery.
In our population, only five cases required systemic therapy, according to study indications, and mupirocin resistance was not detected during follow-up.
The inclusion of ISTODAX in the NCCN Guidelines is an important step forward in potentially improving clinical outcomes for patients with CTCL who have received prior systemic therapy," said Alan Colowick, MD, Chief Executive Officer of Gloucester Pharmaceuticals.
KEYNOTE-224 is a registrational, open-label phase 2 trial investigating Keytruda monotherapy in patients with advanced HCC who had previously received systemic therapy with sorafenib.
Merck announced findings from the registrational phase 2 KEYNOTE-224 trial investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in patients with advanced hepatocellular carcinoma, the most common type of liver cancer, who were previously treated with systemic therapy.
The US Food and Drug Administration (FDA) has approved US-based Kite Pharma's chimeric antigen receptor T cell therapy, Yescarta (axicabtagene ciloleucel), intended for the treatment of relapsed or refractory large B-cell lymphoma in adult patients who had at least two lines of systemic therapy, it was reported on Friday.
Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better and had fewer adverse outcomes than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute (NEI).
Sidbury said that systemic therapy for atopic dermatitis is indicated only when control is inadequate despite truly optimized topical care, and the condition is having a "significant negative physical, psychological, or social impact" on the patient.